A randomized, double-blind, placebo-controlled trial evaluated the effectiveness of baricitinib plus remdesivir in hospitalized adults with Covid-19. The study enrolled 1033 patients, with 515 assigned to the combination treatment group and 518 to the control group. The primary outcome was the time to recovery, which was significantly shorter in the combination group (7 days) compared to the control group (8 days). The combination treatment also showed a 30% higher odds of improvement in clinical status at day 15. Patients receiving high-flow oxygen or noninvasive ventilation had a faster recovery with combination treatment (10 days) compared to the control group (18 days). The 28-day mortality rate was lower in the combination group (5.1%) than in the control group (7.8%). The combination treatment was associated with fewer serious adverse events and new infections compared to the control group. Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating clinical improvement, particularly in patients requiring high-flow oxygen or noninvasive ventilation. The combination treatment was also associated with fewer serious adverse events. The study was funded by the National Institute of Allergy and Infectious Diseases. The results suggest that baricitinib plus remdesivir is a safe and effective treatment for hospitalized adults with Covid-19.A randomized, double-blind, placebo-controlled trial evaluated the effectiveness of baricitinib plus remdesivir in hospitalized adults with Covid-19. The study enrolled 1033 patients, with 515 assigned to the combination treatment group and 518 to the control group. The primary outcome was the time to recovery, which was significantly shorter in the combination group (7 days) compared to the control group (8 days). The combination treatment also showed a 30% higher odds of improvement in clinical status at day 15. Patients receiving high-flow oxygen or noninvasive ventilation had a faster recovery with combination treatment (10 days) compared to the control group (18 days). The 28-day mortality rate was lower in the combination group (5.1%) than in the control group (7.8%). The combination treatment was associated with fewer serious adverse events and new infections compared to the control group. Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating clinical improvement, particularly in patients requiring high-flow oxygen or noninvasive ventilation. The combination treatment was also associated with fewer serious adverse events. The study was funded by the National Institute of Allergy and Infectious Diseases. The results suggest that baricitinib plus remdesivir is a safe and effective treatment for hospitalized adults with Covid-19.